- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Purpose Bitcoin ETF
Silver47 Exploration
Syntheia
Black Swan Graphene
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Abacus Health Products Scores Partnership with Rob Gronkowski
The now-retired NFL player will act as a spokesperson for pain relief products from hemp-derived CBD maker Abacus Health under a new partnership.
Hemp-derived cannabidiol (CBD) manufacturer Abacus Health Products (CSE:ABCS,OTCQX:ABAHF) has scored an endorsement deal with former NFL player Rob Gronkowski, the company announced on Tuesday (August 27).
In a press release, the company confirmed Gronkowski will act as a spokesperson for its CBD recovery products. He will participate in the marketing of new products, and Abacus also teased that Gronkowski could help in the development of new CBD items.
“(Gronkowski’s) passion for living life to the fullest while maintaining a healthy, natural, and pain-free lifestyle aligns perfectly with the mission of our company,” said Perry Antelman, CEO of Abacus.
Shares of the CBD producer jumped following the announcement. They opened at a price of C$7.37, and, as of 12:48 p.m. EDT, had increased in value by 4.9 percent to C$7.40.
After more than a decade of living with pain, I started using @cbdmedic_pharma products for recovery and I was blown away. So proud to partner with these guys https://t.co/Re8r1b6MXq
— Rob Gronkowski (@RobGronkowski) August 27, 2019
In a statement, Gronkowski said after his retirement he started exploring options to treat his pain from playing football. Gronkowski began his professional career in the NFL in 2010, and suffered a variety of injuries during that time. Gronkowski officially retired from the NFL in March after playing his entire career with the New England Patriots. The tight end won three Super Bowls with the Patriots.
“During my career, I pushed myself while recovering from nine surgeries and countless injuries,” said Gronkowski. “I was in near constant pain and needed to make a change.”
During a press conference, Gronkowski said he is now pain free thanks to CBD products, and asked major sports leagues to update their policies on the drug.
Other retired NFL players have come forward with support for the marijuana industry as a way to manage pain from playing the sport. However, the football league continues to evaluate the drug without committing to a change in its ban on marijuana products.
Business opportunities for athletes in the cannabis industry have also flourished. Ex-NFL player Tiki Barber acts as the chief business development officer for Grove Group Management, a private equity and venture capital firm he helped launch in 2018.
Abacus currently promotes two brands with different lines of pain management products: CBD Medic and CBD Clinic. The first line also contains a line of skincare products.
As part of an investor deck, the company confirmed it has secured distribution channels with national retailers in the US.
The company reported revenues of US$3.2 million for Q2 2019, representing a minor drop from its Q1 2019 results of US$3.8 million.
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.